Treatment sequencing in metastatic castrate-resistant prostate cancer

Six different treatments have demonstrated improved survival in phase III trials targeted to patients with metastatic castration-resistant prostate cancer (mCRPC). Front-line therapeutic options for mCRPC include docetaxel, sipuleucel-T, abiraterone and radium-223. Post-docetaxel options include cab...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartor, Oliver, Gillessen, Silke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023372/
https://www.ncbi.nlm.nih.gov/pubmed/24675654
http://dx.doi.org/10.4103/1008-682X.126378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023372/
https://www.ncbi.nlm.nih.gov/pubmed/24675654
http://dx.doi.org/10.4103/1008-682X.126378

Ejemplares similares